D91F99Z
Brachytherapy Oropharynx to None with Iodine 125 (I-125), High Dose Rate (HDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | 9 Ear, Nose, Mouth and Throat |
| Operation | 1 Brachytherapy |
| Body Part | F Oropharynx |
| Approach | 9 High Dose Rate (HDR) |
| Device | 9 Iodine 125 (I-125) |
| Qualifier | Z None |
Procedure Overview
Brachytherapy for ear, nose, mouth, and throat conditions involves placing a radioactive source directly into or next to a tumor, commonly in the oral cavity, tongue base, or nasopharynx. Because the source sits so close to the target tissue, it delivers a concentrated dose to the tumor while limiting exposure to surrounding healthy structures, which is valuable in a region crowded with nerves and tissue responsible for speech and swallowing.
The radioactive material may be temporary, removed after a set period, or permanently implanted depending on the isotope and clinical goal. This approach is often used alongside external beam radiation or surgery, particularly when a tumor recurs or when sparing normal tissue is a priority.
Anatomy & Axis Detail
Oropharynx
The oropharynx encompasses the base of tongue, tonsils, soft palate, and posterior pharyngeal wall, a region increasingly associated with HPV-related squamous cell carcinoma in addition to traditional smoking-related disease. Brachytherapy in this area is most often used as a boost to the primary tumor bed following external beam radiation and chemotherapy, delivered through interstitial needle implants placed transorally into the tongue base or tonsillar region, sometimes with image guidance to account for the irregular contours of the pharyngeal musculature. The dense concentration of swallowing and airway structures in this space means catheter placement must be planned to minimize dose to uninvolved mucosa and the contralateral side when disease is unilateral. Records should specify the oropharyngeal subsite and implant technique used.
Modality Qualifier: High Dose Rate (HDR)
High Dose Rate (HDR) identifies brachytherapy delivered with a radioactive source of high activity, allowing treatment to be completed in minutes per fraction, often on an outpatient basis with afterloading applicators. It contrasts with Low Dose Rate (LDR), which uses a weaker source left in place for hours to days, trading a longer treatment time for a different radiobiological effect and staffing exposure profile.
Isotope: Iodine 125 (I-125)
Iodine-125 is a low-energy, low-dose-rate radioisotope most often loaded into small permanent seeds implanted directly into tissue, commonly for early-stage prostate cancer or ocular tumors via plaque brachytherapy. Its longer half-life (about 60 days) gives a slower, more protracted dose delivery than Pd-103 or Cs-131, which is the key distinction among the permanent-seed isotopes.
Coding & Documentation
Coders need documentation identifying the specific isotope or source used and confirming that the radioactive material was placed within or immediately adjacent to the target structure, not delivered from an external machine. The procedure note should specify whether the source is temporary or permanent, since this affects the qualifier assigned.